NCT04013958 is a Phase 3 clinical trial of IV Ketamine in Acute Pain, sponsored by Tel-Aviv Sourasky Medical Center.

Who is sponsoring NCT04013958?

NCT04013958 is sponsored by Tel-Aviv Sourasky Medical Center.

What drugs are being tested in NCT04013958?

Interventions in NCT04013958: IV Ketamine, IM Ketamine.

What condition does NCT04013958 study?

NCT04013958 studies Acute Pain, Renal Colic.

Is NCT04013958 still recruiting?

NCT04013958 is currently status unknown. Last updated 10 July 2019.

Last reviewed 2019-07-10 · How we verify

NCT04013958

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison of Treatment by IM Ketamine to IV Ketamine in Patients With Renal Colic

Status unknown Phase 3 Last updated 10 July 2019

What this trial tests

Phase 3 trial testing IV Ketamine in Acute Pain in 100 participants. Status unknown.

Timeline

1 August 2019

Primary endpoint
1 August 2021

1 August 2021

Quick facts

Lead sponsor	Tel-Aviv Sourasky Medical Center
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	supportive care
Enrollment	100
Start date	1 August 2019
Primary completion	1 August 2021
Estimated completion	1 August 2021
Sites	1 location across Israel

Drugs / interventions tested

IV Ketamine — full drug profile →
IM Ketamine — full drug profile →

Conditions studied

Acute Pain — all drugs for Acute Pain →
Renal Colic — all drugs for Renal Colic →

Sponsor

Tel-Aviv Sourasky Medical Center

Who can join

Adults 18 to 70, any sex, with Acute Pain or Renal Colic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients who present to the emergency department (ED), with acute pain due to renal colic, are often treated with opioids. Treatment with opioids has many disadvantages - cardio-respiratory depression, nausea, vomiting and long term dependence. For these reasons, there is a constant search for a way to reduce the use of opioids. ketamine has been proven to augmented the analgesic effect of opioids, and thus reduce the use and adverse effects of opioids. Different studies about the use of Ketamine as a sedition agent have shown that Ketamine given IM versus IV has longer duration of effect with less adverse effects. The study we are conducting is designed to test and analyze the safety and efficacy of IV Ketamine with IV Morphine compared to IV Ketamine and morphine with IM placebo in a setting of acute pain due to, or suspected renal colic in the ED. When both ways of administration are given by the protocol as is customary for treatment of pain in the Emergency Medicine department, and will be a prospective, randomized, double blind, controlled study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of IV Ketamine

Trials testing the same drug.

NCT03751423 — Intravenous Ketamine for Pain Control During First Trimester Surgical Abortion · Phase 3 · suspended

Other recruiting trials for Acute Pain

Currently open trials in the same condition.

NCT06779604 — Dexmedetomidine and Dexamethasone Added as Adjuvant Infraclavicular Brachial Plexus Block in Upper Limb Surgery · recruiting
NCT07348419 — Quadro-Iliac vs Thoracolumbar Interfascial Plane Block for Analgesia After Single-Level Lumbar Disc Surgery · NA · recruiting
NCT07335159 — Does Patient Testimonial Improve the Pain Relief Derived From a Brief Intervention · NA · recruiting
NCT07348523 — Comparison of the Postoperative Analgesic Efficacy of Classical and Modified Erector Spinae Plane Blocks After Lumbar Sp · NA · recruiting
NCT07336264 — Characterization of Acute Pain · recruiting

Other Tel-Aviv Sourasky Medical Center trials

Trials by the same sponsor.

NCT07380737 — Feasibility and Preliminary Effects of the Walking Tall App for Home-Based Gait Training in Parkinson's Disease: A Pilot · NA · recruiting
NCT07104136 — Improving Adherence to COPD Treatments in Primary Care · NA · enrolling by invitation
NCT07327021 — MRI-Guided Neoadjuvant Treatment De-Escalation in Stage II-III TNBC · Phase 2 · recruiting
NCT07191249 — A Phase 2, Multicenter, Open-Label Trial to Evaluate Efficacy and Safety of Subcutaneous (SC) Mosunetuzumab in Previousl · Phase 2 · not yet recruiting
NCT07235332 — Assessing Toxic Metal Exposure From Vegetarian/Vegan, Omnivorous, and Low-carb Diets in Israel. · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04013958 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tel-Aviv Sourasky Medical Center
Last refreshed: 10 July 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04013958.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing